ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 17, 2018

Appointment of NOMAD

Read More
December 07, 2018

Update on Corporate Activities

Read More
November 01, 2018

Nominated Adviser Status

Read More
September 26, 2018

Interim results announcement for the six months ended 30 June 2018

Read More
September 19, 2018

Standford Capital Partners and Si Capital are appointed as joint broker

Read More
September 07, 2018

IMM September 2018 Corporate Update

Read More
June 29, 2018

2018 Annual General Meeting – All Resolutions Passed

Read More
June 14, 2018

ImmuPharma announces positive pre-clinical data on its CIDP programme

Read More
June 06, 2018

Annual Report and Accounts Posted to Shareholders

Read More
May 29, 2018

Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort<sup>1</sup>

Read More
April 24, 2018

Holding in company

Read More
April 23, 2018

Immupharma PLC confident on Lupuzor’s™ future

Read More
  • 1
  • 2
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved